CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 79 enrolled
Drug / intervention
RPL554 Suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03673670
NCT03673670Phase 2Completed
CompareCT.gov

A Phase II, Randomized, Double Blind, Placebo Controlled, Three-way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered in Addition to Open Label Tiotropium/Olodaterol in Patients With COPD

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA·interventional·Posted Sep 17, 2018·Updated Oct 10, 2019

In Brief

A Phase 2 clinical trial evaluating RPL554 Suspension, Placebo, and 1 other intervention for COPD. Completed, enrolled 79 participants across 4 sites in 2 countries.

Detailed Summary

The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol (Respimat) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will receive each of the three treatment combinations in a randomized sequence using a crossover design

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 17, 2018
Enrollment StartJul 16, 2018
Primary CompletionNov 13, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.8 years ago

Interventions

RPL554 Suspensiondrug

A PDE3/4 inhibitor

Placebodrug

A placebo solution

Tiotropium/olodaterol (Respimat)drug

An anticholinergic/β-agonist combination medication